2026 EHA Global Hematology Congress In-Depth Analysis Report

The 31st EHA Congress in Stockholm marks a paradigm shift across hematologic malignancies. Five forces dominate: bispecific antibodies become new standards, menin inhibitors break through in AML, non-covalent BTK + next-gen BCL2 reshape CLL, MRD-driven fixed-duration strategies prevail, and CAR-T enters multi-generation upgrades. MonumenTAL-3 delivers a 72% PFS risk reduction (triplet) and 67% (doublet) in RRMM, while KOMET-007 demonstrates 90–96% CRc and >80% MRD-negativity in NPM1m/KMT2A-r AML — the field is now defined by deep, durable, MRD-guided remissions. Janssen consolidates MM leadership (teclistamab + talquetamab dual track); BeiGene's zanubrutinib + sonrotoclax all-oral combo challenges venetoclax+obinutuzumab in frontline CLL.